SCHEMBL2918680

SCHEMBL2918680

O=C(O)c1nn(-c2ccccc2)c(-c2ccccc2)c1F

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 4/20 0.55
CYP2C19 P33261 3/20 0.55
CYP1A2 P05177 2/20 0.55
ALDH1A1 P00352 3/20 0.50
CYP3A4 P08684 2/20 0.50
NPSR1 Q6W5P4 2/20 0.50
CA1 P00915 1/20 0.50
CA2 P00918 1/20 0.50
MAPT P10636 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
MAPK1 P28482 1/20 0.48
RPA1 P27694 1/20 0.46
CNR1 P21554 1/20 0.46
CNR2 P34972 1/20 0.46
PTGS1 P23219 2/20 0.45
PTGS2 P35354 2/20 0.45
POLB P06746 1/20 0.45
PTGER1 P34995 1/20 0.45
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2915869 0.81 CYP2C9 (0.63) CYP2C9CYP2C19CYP1A2ALDH1A1CYP3A4
SCHEMBL2918809 0.81 ALDH1A1 (0.70) CYP2C9CYP2C19ALDH1A1CYP3A4NPSR1
SCHEMBL2913926 0.79 MGLL (0.50) CYP2C9CYP2C19CYP1A2ALDH1A1CYP3A4
SCHEMBL10357411 0.78 CYP2C9 (0.64) CYP2C9CYP2C19CYP1A2ALDH1A1CYP3A4
SCHEMBL3822877 0.77 KDM4E (0.59) CYP2C9CYP2C19CYP1A2ALDH1A1CYP3A4
SCHEMBL6123547 0.77 ALDH1A1 (0.56) CYP2C9CYP2C19CYP1A2ALDH1A1CYP3A4
SCHEMBL6123601 0.77 CYP2C9 (0.51) CYP2C9CYP2C19CYP1A2ALDH1A1CYP3A4
SCHEMBL13870586 0.77 CYP2C9 (0.51) CYP2C9CYP2C19CYP1A2ALDH1A1CYP3A4
SCHEMBL10357494 0.76 ALDH1A1 (0.56) CYP2C9CYP2C19CYP1A2ALDH1A1CYP3A4
SCHEMBL13212913 0.74 KDM4C (0.49) CYP2C9CYP2C19CYP1A2ALDH1A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1591443-B1 PYRAZOLE DERIVATIVE DAIICHI SANKYO CO LTD (JP) 2010-08-25 EP disclosed
US-7622471-B2 Pyrazole derivatives having a pyridazine and pyridine functionality DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2009-11-24 US disclosed
US-7622471-B2 Pyrazole derivatives having a pyridazine and pyridine functionality DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2009-11-24 US disclosed
US-7622471-B2 Pyrazole derivatives having a pyridazine and pyridine functionality DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2009-11-24 US disclosed
CN-100436445-C Pyrazole derivative DAIICHI SEIYAKU CO (JP) 2008-11-26 CN disclosed
US-20060128685-A1 Pyrazole derivative DAIICHI PHARMACEUTICAL CO., LTD., (JP) 2006-06-15 US disclosed
CN-1759110-A Pyrazole derivatives DAIICHI SEIYAKU CO (JP) 2006-04-12 CN disclosed
EP-1591443-A1 PYRAZOLE DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2005-11-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060128685-A1 Pyrazole derivative PTGS1, PTGS2, PTGER1 CYP2C9 251/4885CYP2C19 129/4885CYP1A2 176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.